ERAS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 21.50%

Insider Buying (Last 12 Months): $3,499,826.50

Insider Selling (Last 12 Months): $0.00

Erasca Insider Trading History Chart

Erasca Share Price & Price History

^$3.28

▲ +0.01 (0.31%)

As of 07/26/2024 01:00 AM ET

Days: 30 | 90 | 365

“Generational Bull Run” Incoming

From Unstoppable Prosperity | Ad

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

Erasca Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/21/2024	Alexander W Casdin	Director	Buy	80,000	$2.27	$181,600.00	573,974
12/6/2023	Valerie Denise Harding Start	Director	Buy	10,000	$1.85	$18,500.00	20,000
12/5/2023	Jonathan E Lim	CEO	Buy	721,850	$1.69	$1,219,926.50	12,899,360
12/4/2023	Alexander W Casdin	Director	Buy	30,000	$1.66	$49,800.00	493,974
10/5/2023	Jonathan E Lim	CEO	Buy	1,000,000	$2.03	$2,030,000.00	19,456,216
6/8/2023	Jonathan E Lim	CEO	Buy	100,000	$2.75	$275,000.00	18,396,216
4/10/2023	Alexander W Casdin	Director	Buy	20,000	$2.76	$55,200.00	463,974
3/28/2023	Jonathan E Lim	CEO	Buy	100,000	$2.84	$284,000.00	18,296,216
1/10/2023	Jonathan E Lim	CEO	Buy	60,000	$3.86	$231,600.00	20,256,222
12/21/2022	Valerie Denise Harding Start	Director	Buy	10,000	$4.64	$46,400.00	10,000
12/15/2022	Alexander W Casdin	Director	Buy	20,000	$4.87	$97,400.00	443,974
12/14/2022	Jonathan E Lim	CEO	Buy	40,000	$4.99	$199,600.00	20,196,222
12/13/2022	Bihua Chen	Director	Buy	307,692	$6.50	$1,999,998.00	10,813,246

“Generational Bull Run” Incoming

From Unstoppable Prosperity | Ad

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

SEC Filings (Institutional Ownership Changes) for Erasca (NASDAQ:ERAS)

67.78% of Erasca stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Erasca Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
7/26/2024	Bank of New York Mellon Corp	392,490	$0.93M	0.0%	+50.6%	0.226%
7/16/2024	Edmonds Duncan Registered Investment Advisors LLC	34,280	$81K	0.0%	+41.2%	0.020%
7/12/2024	SG Americas Securities LLC	22,890	$54K	0.0%	-38.1%	0.013%
5/14/2024	EntryPoint Capital LLC	32,087	$66K	0.1%	-60.2%	0.019%
5/10/2024	Acadian Asset Management LLC	346,953	$0.71M	0.0%	+286.5%	0.200%
5/10/2024	Vanguard Group Inc.	4,338,108	$8.94M	0.0%	+14.4%	2.502%
5/7/2024	Susquehanna Fundamental Investments LLC	104,691	$0.22M	0.0%	N/A	0.060%
5/7/2024	CVI Holdings LLC	1,456,311	$3M	2.9%	N/A	0.840%
5/7/2024	SG Americas Securities LLC	36,997	$76K	0.0%	-22.8%	0.021%
5/3/2024	GSA Capital Partners LLP	569,039	$1.17M	0.1%	-14.8%	0.328%
4/29/2024	China Universal Asset Management Co. Ltd.	29,013	$60K	0.0%	+66.1%	0.017%
4/25/2024	Aaron Wealth Advisors LLC	27,735	$57K	0.0%	+107.5%	0.018%
4/11/2024	Sanders Morris Harris LLC	12,000	$25K	0.0%	-97.9%	0.008%
2/22/2024	Sierra Summit Advisors LLC	105,711	$0.23M	0.1%	N/A	0.070%
2/15/2024	PFM Health Sciences LP	2,575,511	$5.49M	0.3%	-34.5%	1.705%
2/14/2024	Pennant Investors LP	166,200	$0.35M	0.1%	N/A	0.110%
2/14/2024	Pale Fire Capital SE	186,101	$0.40M	0.1%	+342.0%	0.123%
2/13/2024	Armistice Capital LLC	8,096,000	$17.24M	0.2%	-3.1%	5.358%
2/12/2024	RPO LLC	20,854	$44K	0.1%	N/A	0.014%
2/8/2024	Vanguard Personalized Indexing Management LLC	16,504	$35K	0.0%	N/A	0.011%
2/6/2024	Swiss National Bank	148,800	$0.32M	0.0%	-18.4%	0.098%
2/2/2024	Bailard Inc.	50,000	$0.11M	0.0%	N/A	0.033%
1/26/2024	Aaron Wealth Advisors LLC	13,368	$28K	0.0%	N/A	0.009%
1/24/2024	China Universal Asset Management Co. Ltd.	17,472	$37K	0.0%	+350.9%	0.012%
1/19/2024	Denali Advisors LLC	91,200	$0.19M	0.1%	-19.0%	0.060%
1/12/2024	SG Americas Securities LLC	47,912	$0.10M	0.0%	+24.4%	0.032%
1/11/2024	Sanders Morris Harris LLC	575,189	$1.25M	0.6%	+35.2%	0.381%
1/5/2024	Exchange Traded Concepts LLC	54,339	$0.12M	0.0%	+34.0%	0.036%
11/15/2023	GSA Capital Partners LLP	404,082	$0.80M	0.1%	+57.4%	0.267%
11/15/2023	Armistice Capital LLC	8,356,000	$16.46M	0.3%	+6.4%	5.530%
11/14/2023	Pale Fire Capital SE	42,101	$83K	0.0%	N/A	0.028%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	191,470	$0.38M	0.0%	-5.8%	0.127%
11/13/2023	Algert Global LLC	313,945	$0.62M	0.0%	+7.3%	0.208%
11/8/2023	Swiss National Bank	182,300	$0.36M	0.0%	+11.2%	0.121%
11/7/2023	Barclays PLC	42,928	$85K	0.0%	+14.0%	0.028%
11/2/2023	Principal Financial Group Inc.	40,376	$80K	0.0%	+14.1%	0.027%
10/25/2023	Zurcher Kantonalbank Zurich Cantonalbank	34,421	$68K	0.0%	+207.5%	0.023%
10/20/2023	Denali Advisors LLC	112,600	$0.22M	0.1%	N/A	0.075%
10/18/2023	Exchange Traded Concepts LLC	40,560	$80K	0.0%	-16.4%	0.027%
10/13/2023	SG Americas Securities LLC	38,521	$76K	0.0%	N/A	0.026%
10/13/2023	Sanders Morris Harris LLC	425,297	$0.82M	0.2%	N/A	0.282%
9/21/2023	Barclays PLC	37,647	$0.10M	0.0%	-32.3%	0.025%
8/14/2023	Prosight Management LP	1,557,370	$4.30M	1.3%	+32.1%	1.031%
8/14/2023	Prelude Capital Management LLC	14,300	$39K	0.0%	N/A	0.009%
8/14/2023	Graham Capital Management L.P.	58,921	$0.16M	0.0%	+459.7%	0.039%
8/7/2023	Principal Financial Group Inc.	35,382	$98K	0.0%	+33.8%	0.023%
8/4/2023	American International Group Inc.	38,840	$0.11M	0.0%	+11.3%	0.026%
8/3/2023	Innovis Asset Management LLC	91,800	$0.25M	0.1%	+111.3%	0.061%
7/24/2023	Allspring Global Investments Holdings LLC	15,478	$43K	0.0%	-21.6%	0.010%
7/20/2023	Exchange Traded Concepts LLC	48,513	$0.13M	0.0%	N/A	0.032%
7/18/2023	Allspring Global Investments Holdings LLC	15,478	$43K	0.0%	-21.6%	0.010%
5/18/2023	International Biotechnology Trust PLC	1,426,000	$4.28M	1.2%	N/A	0.947%
5/16/2023	Armistice Capital LLC	7,350,000	$22.12M	0.3%	+172.2%	4.881%
5/12/2023	Prosight Management LP	1,179,090	$3.55M	1.7%	N/A	0.783%
5/12/2023	Martingale Asset Management L P	11,032	$33K	0.0%	N/A	0.007%
5/10/2023	Innovis Asset Management LLC	43,437	$0.13M	0.1%	+94.3%	0.029%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	167,741	$0.51M	0.0%	N/A	0.111%
5/9/2023	Y Intercept Hong Kong Ltd	23,306	$70K	0.0%	N/A	0.015%
5/9/2023	Russell Investments Group Ltd.	88,275	$0.27M	0.0%	N/A	0.059%
5/8/2023	Zurcher Kantonalbank Zurich Cantonalbank	11,193	$34K	0.0%	+63.6%	0.007%
5/5/2023	Regents of The University of California	236,236	$0.71M	0.1%	-49.0%	0.157%
5/3/2023	Jump Financial LLC	227,400	$0.68M	0.0%	+154.9%	0.151%
5/3/2023	Integrated Wealth Concepts LLC	21,000	$63K	0.0%	N/A	0.014%
4/27/2023	Arizona State Retirement System	19,956	$60K	0.0%	N/A	0.013%
2/15/2023	Armistice Capital LLC	2,700,000	$11.64M	0.2%	N/A	2.207%
2/13/2023	Dark Forest Capital Management LP	9,081	$39K	0.0%	N/A	0.007%
2/13/2023	GSA Capital Partners LLP	56,281	$0.24M	0.0%	N/A	0.046%
2/13/2023	Artal Group S.A.	4,710,682	$20.30M	1.1%	+48.5%	3.850%
2/13/2023	Cornercap Investment Counsel Inc.	55,066	$0.24M	0.0%	N/A	0.045%
2/9/2023	Citigroup Inc.	127,756	$0.55M	0.0%	+54.4%	0.104%
2/8/2023	Swiss National Bank	161,200	$0.70M	0.0%	+125.1%	0.132%
2/8/2023	Oppenheimer & Co. Inc.	26,287	$0.11M	0.0%	+100.0%	0.021%
2/7/2023	Edge Capital Group LLC	207,874	$0.90M	0.1%	N/A	0.170%
2/2/2023	Regents of The University of California	462,972	$2M	0.4%	-2.0%	0.378%
2/1/2023	Zurcher Kantonalbank Zurich Cantonalbank	6,842	$29K	0.0%	-46.2%	0.006%
11/15/2022	PFM Health Sciences LP	7,264,981	$56.67M	2.1%	+23.5%	5.937%
11/15/2022	Quantamental Technologies LLC	10,460	$82K	0.0%	N/A	0.009%
11/9/2022	Zurcher Kantonalbank Zurich Cantonalbank	12,725	$99K	0.0%	+161.5%	0.010%
11/8/2022	New York State Common Retirement Fund	43,752	$0.34M	0.0%	+48.7%	0.036%
11/4/2022	First Republic Investment Management Inc.	15,200	$0.12M	0.0%	N/A	0.012%
11/3/2022	Teacher Retirement System of Texas	10,025	$78K	0.0%	N/A	0.008%
11/3/2022	The Manufacturers Life Insurance Company	27,121	$0.21M	0.0%	-5.2%	0.022%
11/3/2022	Barclays PLC	57,088	$0.45M	0.0%	+852.4%	0.047%
11/3/2022	Regents of The University of California	472,472	$3.69M	0.7%	-48.1%	0.387%
10/31/2022	SG Americas Securities LLC	21,517	$0.17M	0.0%	+30.5%	0.018%
10/26/2022	Allspring Global Investments Holdings LLC	20,029	$0.16M	0.0%	-44.0%	0.016%
8/16/2022	Woodline Partners LP	362,146	$2.02M	0.0%	-21.0%	0.296%
8/15/2022	Laurion Capital Management LP	23,100	$0.13M	0.0%	N/A	0.019%
8/12/2022	Virtus ETF Advisers LLC	21,337	$0.12M	0.0%	+85.0%	0.018%
8/12/2022	FMR LLC	18,278,655	$101.81M	0.0%	+2.6%	15.000%
8/11/2022	Trexquant Investment LP	70,281	$0.39M	0.0%	N/A	0.058%
8/11/2022	Alps Advisors Inc.	72,285	$0.40M	0.0%	N/A	0.059%
8/9/2022	Swiss National Bank	71,600	$0.40M	0.0%	+24.7%	0.059%
8/5/2022	M&T Bank Corp	25,540	$0.14M	0.0%	N/A	0.021%
8/5/2022	Regents of The University of California	911,168	$5.08M	1.0%	N/A	0.748%
8/1/2022	ProShare Advisors LLC	16,775	$93K	0.0%	-31.6%	0.014%
7/29/2022	SG Americas Securities LLC	16,491	$92K	0.0%	N/A	0.014%
7/26/2022	Mirae Asset Global Investments Co. Ltd.	21,385	$0.12M	0.0%	N/A	0.018%
7/25/2022	Allspring Global Investments Holdings LLC	35,775	$0.20M	0.0%	+9.0%	0.029%
7/12/2022	Exane Derivatives	14,377	$80K	0.0%	N/A	0.012%

Data available starting January 2016

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Today's Range

Now: $3.28

$3.20

$3.45

50 Day Range

MA: $2.52

$2.00

$3.28

52 Week Range

Now: $3.28

$1.51

$3.45

Volume

1,377,754 shs

Average Volume

1,491,211 shs

Market Capitalization

$568.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.16

Who are the company insiders with the largest holdings of Erasca?: Erasca's top insider investors include:
Jonathan E Lim (CEO)
Bihua Chen (Director)
Alexander W Casdin (Director)
Valerie Denise Harding Start (Director)
Learn More about top insider investors at Erasca.
Who are the major institutional investors of Erasca?: Erasca's top institutional investors include:
Bank of New York Mellon Corp — 0.23%
Edmonds Duncan Registered Investment Advisors LLC — 0.02%
SG Americas Securities LLC — 0.01%
Learn More about top institutional investors of Erasca stock.
Which institutional investors are selling Erasca stock?: During the last quarter, ERAS stock was sold by these institutional investors:
SG Americas Securities LLC
Which institutional investors are buying Erasca stock?: Within the last quarter, ERAS stock was bought by institutional investors including:
Bank of New York Mellon Corp
Edmonds Duncan Registered Investment Advisors LLC
In the previous year, these company insiders have bought Erasca stock:
Jonathan E Lim (CEO)
Bihua Chen (Director)
Alexander W Casdin (Director)
Valerie Denise Harding Start (Director)
Learn More investors buying Erasca stock.